REFERENCES

1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79.

2. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-62.

3. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v28-37.

4. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010;2:419-27.

5. Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare. PLoS One 2017;12:e0186643.

6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 2017;24:1073274817729245.

7. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76.

8. Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int 2015;35:1048-53.

9. Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, et al. New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells 2020;9:688.

10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84.

11. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.

12. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658-67.

13. Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018;105:192-202.

14. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73.

15. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 2015;15:564.

16. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-40.

17. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011;117:1498-505.

18. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012;24:437-43.

19. Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011;66:322-8.

20. Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-16.

21. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-8.

22. Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford) 2017;19:741-8.

23. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 2019;37:1015-27.

24. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.

25. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005;35:68-73.

26. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010;79:39-45.

27. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279-81.

28. Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, et al. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM). Ann Oncol 2006;17:vii73-7.

29. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.

30. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469-74.

31. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014;25:391-8.

32. Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 2019;30:1950-8.

33. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-43.

34. Kim ST, Kang JH, Lee J, Lee HW, Oh SY, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 2019;30:788-95.

35. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:1707-12.

36. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 2019;5:824-30.

37. Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, et al. 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 2018;29.

38. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396-400.

39. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000;23:425-8.

40. Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998;9:393-7.

41. Petekkaya I, Gezgen G, Roach EC, Solak M, Gullu I. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine. J buon 2012;17:796.

42. Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, et al. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors. Liver Int 2019;39:914-23.

43. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 2014;110:2165-9.

44. Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer 2015;121:3290-7.

45. Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, et al. Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer 2019;111:94-106.

46. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014;25:2328-38.

47. Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol 2019;37:4003.

48. Zheng Y, Tu X, Zhao P, Jiang W, Liu L, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018;119:291-5.

49. Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 2017;116:561-7.

50. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003-10.

51. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018;15:95-111.

52. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383.

53. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014;19:235-42.

54. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.

55. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84.

56. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018;36:276-82.

57. Goyal L, Meric-Bernstein F, Hollebecque A, Valle J, Morizane C, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol 2020;38:108.

58. Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, et al. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs 2018;36:424-34.

59. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019;120:165-71.

60. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72-9.

61. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 2016;27:599-608.

62. Abou-Alfa GK, Macarulla T, Javle M, Kelley RK, Lubner SJ, et al. ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol 2019;30. Abstract LBA 10_PR

63. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6:e15640.

64. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A 2013;110:19513-8.

65. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.

66. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82.

67. Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017;36:141-57.

68. Jensen LH. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opin Investig Drugs 2016;25:359-65.

69. Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. In Vivo 2020;34:479-88.

70. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-8.

71. Vogel A, Kasper S, Bitzer M, Block A, Sinn M, et al. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Eur J Cancer 2018;92:11-9.

72. Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007;33:1025-9.

73. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003;63:1083-92.

74. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11:48-54.

75. Bréchon M, Dior M, Dréanic J, Brieau B, Guillaumot MA, et al. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Invest New Drugs 2018;36:156-62.

76. Valle J, Bai LY, Orlova R, Van Cutsem E, Adeva J, et al. Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): a randomized, double-blind, phase II study. J Clin Oncol 2020;38. Abstract 477

77. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 2018;23:1407-e136.

78. Yang XW, Li L, Hou GJ, Yan XZ, Xu QG, et al. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome. Oncotarget 2017;8:7710-21.

79. Dokduang H, Techasen A, Namwat N, Khuntikeo N, Pairojkul C, et al. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepatobiliary Pancreat Sci 2014;21:767-76.

80. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 2011;105:131-8.

81. Pant S, Saleh M, Bendell J, Infante JR, Jones S, et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014;25:1416-21.

82. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10.

83. Silva VW, Askan G, Daniel TD, Lowery M, Klimstra DS, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 2016;5:62.

84. Bang YJ, Ueno M, Malka D, Chung HC, Nagrial A, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol 2019;37:4079.

85. Gou M, Zhang Y, Si H, Dai G. Efficacy and safety of nivolumab for metastatic biliary tract cancer. Onco Targets Ther 2019;12:861-7.

86. Kim RD, Kim DW, Alese OB, Li D, Shah N, et al. A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). J Clin Oncol 2019;37:4097.

87. Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 2019;4:611-21.

88. Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen JS, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol 2019;37:387.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/